Article
ACAA2 was a predictor for the prognosis and immunotherapy response of hepatocellular carcinoma
2022-06-10
Abstract excerpt
<h4>Background: </h4> Immunotherapy is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, immunotherapy benefits are limited in certain patients. Therefore, identifying effective biomarkers is important for the efficient use of immunotherapy. In the present study, acetyl-CoA acyltransferase 2 (ACAA2), which was decreased during HCC initiation, was identified as a gene of interest. Metho...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d423e48d-988a-52a9-880a-9782825f9c63
- DOI
- 10.21203/rs.3.rs-1726448/v1
